A closer look at nerve growth factor: from biology to clinical trials in ophthalmology

Bibliography

• Aloe L, Rocco ML, Bianchi P, Manni L. Nerve growth factor: from the early. discoveries to the potential clinical use. J Transl Med 2012;10:239
   PubMed Web of Science ®Google Scholar
• Chao MV, Rajagopal R, Lee FS. Neurotrophin signalling in health and disease. Clin Sci (Lond) 2006;110(2):167-73
   PubMed Web of Science ®Google Scholar
• Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987;237(4819):1154-62
   PubMed Web of Science ®Google Scholar
• Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 2001;24:1217-81
   PubMed Web of Science ®Google Scholar
• Schulte-Herbrüggen O, Jockers-Scherübl MC, Hellweg R. Neurotrophins: from pathophysiology to treatment in Alzheimer’s disease. Curr Alzheimer Res 2008;5(1):38-44
   PubMedGoogle Scholar
• Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002;50:393-413
   PubMed Web of Science ®Google Scholar
• Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000;284(17):2215-21
   PubMed Web of Science ®Google Scholar
• McArthur JC, Yiannoutsos C, Simpson DM, et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 2000;54(5):1080-8
   PubMed Web of Science ®Google Scholar
• Lambiase A, Sacchetti M, Bonini S. Nerve growth factor therapy for corneal disease. Curr Opin Ophthalmol 2012;23(4):296-302
   PubMed Web of Science ®Google Scholar
• Lambiase A, Rama P, Bonini S, et al. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med 1998;338(17):1174-80
   PubMed Web of Science ®Google Scholar
• Bonini S, Lambiase A, Rama P, et al. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology 2000;107(7):1347-51; discussion 1351-2
   PubMed Web of Science ®Google Scholar
• Lambiase A, Bonini S, Aloe L, et al. Anti-inflammatory and healing properties of nerve growth factor in immune corneal ulcers with stromal melting. Arch Ophthalmol 2000;118(10):1446-9
   PubMedGoogle Scholar
• Lambiase A, Tirassa P, Micera A, et al. Pharmacokinetics of conjunctivally applied nerve growth factor in the retina and optic nerve of adult rats. Invest Ophthalmol Vis Sci 2005;46(10):3800-6
   PubMed Web of Science ®Google Scholar
• Di Fausto V, Fiore M, Tirassa P, et al. Eye drop NGF administration promotes the recovery of chemically injured cholinergic neurons of adult mouse forebrain. Eur J Neurosci 2007;26(9):2473-80
   PubMed Web of Science ®Google Scholar
• Ferrari MP, Mantelli F, Sacchetti M, et al. Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial. BioDrugs 2014;28(3):275-83
   PubMed Web of Science ®Google Scholar
• Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol 2014;8:571-9
   PubMedGoogle Scholar
• Lambiase A, Rama P, Aloe L, Bonini S. Management of neurotrophic keratopathy. Curr Opin Ophthalmol 1999;10(4):270-6
   PubMedGoogle Scholar
• Kruse FE, Rohrschneider K, Völcker HE. Multilayer amniotic membrane transplantation for reconstruction of deep corneal ulcers. Ophthalmology 1999;106(8):1504-10; discussion 1511
   PubMed Web of Science ®Google Scholar
• Khokhar S, Natung T, Sony P, et al. Amniotic membrane transplantation in refractory neurotrophic corneal ulcers: a randomized, controlled clinical trial. Cornea 2005;24(6):654-60
   PubMed Web of Science ®Google Scholar
• Lugo M, Arentsen JJ. Treatment of neurotrophic ulcers with conjunctival flaps. Am J Ophthalmol 1987;103(5):711-12
   PubMedGoogle Scholar
• Jhanji V, Young AL, Mehta JS, et al. Management of corneal perforation. Surv Ophthalmol 2011;56(6):522-38
   PubMed Web of Science ®Google Scholar
• Lambiase A, Manni L, Bonini S, et al. Nerve growth factor promotes corneal healing: structural, biochemical, and molecular analyses of rat and human corneas. Invest Ophthalmol Vis Sci 2000;41(5):1063-9
   PubMed Web of Science ®Google Scholar
• Sahel J, Bonnel S, Mrejen S, Paques M. Retinitis pigmentosa and other dystrophies. Dev Ophthalmol 2010;47:160-7
   PubMedGoogle Scholar
• Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006;368(9549):1795-809
   PubMed Web of Science ®Google Scholar
• Bunker CH, Berson EL, Bromley WC, et al. Prevalence of retinitis pigmentosa in Maine. Am J Ophthalmol 1984;97(3):357-65
   PubMed Web of Science ®Google Scholar
• Boughman JA, Fishman GA. A genetic analysis of retinitis pigmentosa. Br J Ophthalmol 1983;67(7):449-54
   PubMed Web of Science ®Google Scholar
• Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis 2006;1:40
   PubMed Web of Science ®Google Scholar
• Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 1993;111(6):761-72
   PubMedGoogle Scholar
• Berson EL, Rosner B, Sandberg MA, et al. Vitamin A supplementation for retinitis pigmentosa. Arch Ophthalmol 1993;111(11):1456-9
   PubMedGoogle Scholar
• Berson EL, Rosner B, Sandberg MA, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol 2004;122(9):1297-305
   PubMedGoogle Scholar
• Hoffman DR, Locke KG, Wheaton DH, et al. A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa. Am J Ophthalmol 2004;137(4):704-18
   PubMed Web of Science ®Google Scholar
• Berson EL, Rosner B, Sandberg MA, et al. Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol 2010;128(4):403-11
   PubMed Web of Science ®Google Scholar
• Kumar A, Midha N, Gogia V, et al. Efficacy of oral valproic acid in patients with retinitis pigmentosa. J Ocul Pharmacol Ther 2014;30(7):580-6
   PubMedGoogle Scholar
• Rotenstreich Y, Belkin M, Sadetzki S, et al. Treatment with 9-cis beta-carotene-rich powder in patients with retinitis pigmentosa: a randomized crossover trial. JAMA Ophthalmol 2013;131(8):985-92
   PubMed Web of Science ®Google Scholar
• Merin S, Obolensky A, Farber MD, Chowers I. A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies. J Ocul Pharmacol Ther 2008;24(1):80-6
   PubMedGoogle Scholar
• Vingolo EM, Pelaia P, Forte R, et al. Does hyperbaric oxygen (HBO) delivery rescue retinal photoreceptors in retinitis pigmentosa? Doc Ophthalmol 1998;97(1):33-9
   PubMedGoogle Scholar
• Birch DG, Weleber RG, Duncan JL, et al. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am J Ophthalmol 2013;156(2):283-292.e1
   PubMed Web of Science ®Google Scholar
• Lambiase A, Aloe L. Nerve growth factor delays retinal degeneration in C3H mice. Graefes Arch Clin Exp Ophthalmol 1996;234(Suppl 1):S96-100
   PubMed Web of Science ®Google Scholar
• Amendola T, Aloe L. Developmental expression of nerve growth factor in the eye of rats affected by inherited retinopathy: correlative aspects with retinal structural degeneration. Arch Ital Biol 2002;140(2):81-90
   PubMedGoogle Scholar
• Lenzi L, Coassin M, Lambiase A, et al. Effect of exogenous administration of nerve growth factor in the retina of rats with inherited retinitis pigmentosa. Vision Res 2005;45(12):1491-500
   PubMed Web of Science ®Google Scholar
• Tham YC, Li X, Wong TY, et al. Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040: A Systematic Review and Meta-Analysis. Ophthalmology 2014;121(11):2081-90
   PubMed Web of Science ®Google Scholar
• Quigley HA. Glaucoma. Lancet 2011;377(9774):1367-77
   PubMed Web of Science ®Google Scholar
• Coleman AL. Advances in glaucoma treatment and management: surgery. Invest Ophthalmol Vis Sci 2012;53(5):2491-4
   PubMed Web of Science ®Google Scholar
• The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998;126(4):498-505
   PubMedGoogle Scholar
• Nucci C, Strouthidis NG, Khaw PT. Neuroprotection and other novel therapies for glaucoma. Curr Opin Pharmacol 2013;13(1):1-4
   PubMedGoogle Scholar
• The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5(2):75-92
   PubMed Web of Science ®Google Scholar
• The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5(2):93-107
   PubMed Web of Science ®Google Scholar
• Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5(2):163-78
   PubMed Web of Science ®Google Scholar
• Sacchetti M, Mantelli F, Lambiase A, et al. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. Br J Ophthalmol 2014;98(8):1016-22
   PubMed Web of Science ®Google Scholar
• Mantelli F, Massaro-Giordano M, Macchi I, et al. The cellular mechanisms of dry eye: from pathogenesis to treatment. J Cell Physiol 2013;228(12):2253-6
   PubMed Web of Science ®Google Scholar
• Lambiase A, Bonini S, Micera A, et al. Expression of nerve growth factor receptors on the ocular surface in healthy subjects and during manifestation of inflammatory diseases. Invest Ophthalmol Vis Sci 1998;39(7):1272-5
   PubMed Web of Science ®Google Scholar
• Lambiase A, Bonini S, Manni L, et al. Intraocular production and release of nerve growth factor after iridectomy. Invest Ophthalmol Vis Sci 2002;43(7):2334-40
   PubMed Web of Science ®Google Scholar
• de Castro F, Silos-Santiago I, López de Armentia M, et al. Corneal innervation and sensitivity to noxious stimuli in trkA knockout mice. Eur J Neurosci 1998;10(1):146-52
   PubMedGoogle Scholar
• Chung ES, Lee KH, Kim M, et al. Expression of neurotrophic factors and their receptors in keratoconic cornea. Curr Eye Res 2013;38(7):743-50
   PubMed Web of Science ®Google Scholar
• Blanco-Mezquita T, Martinez-Garcia C, Proença R, et al. Nerve growth factor promotes corneal epithelial migration by enhancing expression of matrix metalloprotease-9. Invest Ophthalmol Vis Sci 2013;54(6):3880-90
   PubMed Web of Science ®Google Scholar
• Kruse FE, Tseng SC. Growth factors modulate clonal growth and differentiation of cultured rabbit limbal and corneal epithelium. Invest Ophthalmol Vis Sci 1993;34(6):1963-76
   PubMed Web of Science ®Google Scholar
• Chen L, Wei RH, Tan DT, et al. Nerve growth factor expression and nerve regeneration in monkey corneas after LASIK. J Refract Surg 2014;30(2):134-9
   PubMed Web of Science ®Google Scholar
• Joo MJ, Yuhan KR, Hyon JY, et al. The effect of nerve growth factor on corneal sensitivity after laser in situ keratomileusis. Arch Ophthalmol 2004;122(9):1338-41
   PubMedGoogle Scholar
• Lambiase A, Aloe L, Mantelli F, et al. Capsaicin-induced corneal sensory denervation and healing impairment are reversed by NGF treatment. Invest Ophthalmol Vis Sci 2012;53(13):8280-7
   PubMedGoogle Scholar
• Lambiase A, Mantelli F, Sacchetti M, et al. Clinical applications of NGF in ocular diseases. Arch Ital Biol 2011;149(2):283-92
   PubMed Web of Science ®Google Scholar
• Li W, Wen J, Jiang D, Ding J. Effects of nerve growth factor on proliferation and DNA synthesis of cultured human fetal retinal pigment epithelium cells. Yan Ke Xue Bao 2002;18(1):45-8, 29
   PubMedGoogle Scholar
• Kolomeyer AM, Zarbin MA. Trophic factors in the pathogenesis and therapy for retinal degenerative diseases. Surv Ophthalmol 2014;59(2):134-65
   PubMedGoogle Scholar
• Chiaretti A, Falsini B, Servidei S, et al. Nerve growth factor eye drop administration improves visual function in a patient with optic glioma. Neurorehabil Neural Repair 2011;25(4):386-90
   PubMedGoogle Scholar
• Falsini B, Chiaretti A, Barone G, et al. Topical nerve growth factor as a visual rescue strategy in pediatric optic gliomas: a pilot study including electrophysiology. Neurorehabil Neural Repair 2011;25(6):512-20
   PubMed Web of Science ®Google Scholar
• Lambiase A, Aloe L, Centofanti M, et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma. Proc Natl Acad Sci USA 2009. [Epub ahead of print]
   PubMedGoogle Scholar
• Turner JE, Delaney RK. Retinal ganglion cell response to axotomy and nerve growth factor in the regenerating visual system of the newt (Notophthalmus viridescens): an ultrastructural morphometric analysis. Brain Res 1979;171(2):197-212
   PubMedGoogle Scholar
• Siliprandi R, Canella R, Carmignoto G. Nerve growth factor promotes functional recovery of retinal ganglion cells after ischemia. Invest Ophthalmol Vis Sci 1993;34(12):3232-45
   PubMedGoogle Scholar
• Mantelli F, Lambiase A, Colafrancesco V, et al. NGF and VEGF effects on retinal ganglion cell fate: new evidence from an animal model of diabetes. Eur J Ophthalmol 2014;24(2):247-53
   PubMedGoogle Scholar
• Scuderi GL, Cesareo M, Perdicchi A, Recupero SM. Standard automated perimetry and algorithms for monitoring glaucoma progression. Prog Brain Res 2008;173:77-99
   PubMedGoogle Scholar
• Lambiase A, Coassin M, Tirassa P, et al. Nerve growth factor eye drops improve visual acuity and electrofunctional activity in age-related macular degeneration: a case report. Ann Ist Super Sanita 2009;45(4):439-42
   PubMed Web of Science ®Google Scholar
• Calonge M. The treatment of dry eye. Surv Ophthalmol 2001;45(Suppl 2):S227-39
   PubMed Web of Science ®Google Scholar
• Lambiase A, Micera A, Sacchetti M, et al. Alterations of tear neuromediators in dry eye disease. Arch Ophthalmol 2011;129(8):981-6
   PubMedGoogle Scholar
• Lambiase A, Micera A, Pellegrini G, et al. In vitro evidence of nerve growth factor effects on human conjunctival epithelial cell differentiation and mucin gene expression. Invest Ophthalmol Vis Sci 2009;50(10):4622-30
   PubMedGoogle Scholar
• Coassin M, Lambiase A, Costa N, et al. Efficacy of topical nerve growth factor treatment in dogs affected by dry eye. Graefes Arch Clin Exp Ophthalmol 2005;243(2):151-5
   PubMedGoogle Scholar
• Cellini M, Bendo E, Bravetti GO, Campos EC. The use of nerve growth factor in surgical wound healing of the cornea. Ophthalmic Res 2006;38(4):177-81
   PubMedGoogle Scholar
• Wu Y, Chu R, Zhou X, et al. Determination of the nerve growth factor level in the central cornea after LASIK and Epi-LASIK treatment in a rabbit model system. Cornea 2009;28(10):1144-8
   PubMedGoogle Scholar
• Lee HK, Lee KS, Kim HC, et al. Nerve growth factor concentration and implications in photorefractive keratectomy vs laser in situ keratomileusis. Am J Ophthalmol 2005;139(6):965-71
   PubMedGoogle Scholar
• Lambiase A, Manni L, Rama P, Bonini S. Clinical application of nerve growth factor on human corneal ulcer. Arch Ital Biol 2003;141(2-3):141-8
   PubMedGoogle Scholar
• Lambiase A, Coassin M, Costa N, et al. Topical treatment with nerve growth factor in an animal model of herpetic keratitis. Graefes Arch Clin Exp Ophthalmol 2008;246(1):121-7
   PubMedGoogle Scholar
• Mauro C, Pietro L, Emilio CC. The use of nerve growth factor in herpetic keratitis: a case report. J Med Case Rep 2007;1:124
   PubMedGoogle Scholar
• Allen SJ, Watson JJ, Shoemark DK, et al. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther 2013;138(2):155-75
   PubMed Web of Science ®Google Scholar
• Calissano P, Matrone C, Amadoro G. Nerve growth factor as a paradigm of neurotrophins related to Alzheimer’s disease. Dev Neurobiol 2010;70(5):372-83
   PubMed Web of Science ®Google Scholar
• Colafrancesco V, Villoslada P. Targeting NGF pathway for developing neuroprotective therapies for multiple sclerosis and other neurological diseases. Arch Ital Biol 2011;149(2):183-92
   PubMed Web of Science ®Google Scholar
• Pradier P, Jalenques I, Dalle M, et al. Distribution and metabolism patterns of plasma 7S- and beta-NGF in the adult male rat. J Physiol Paris 1994;88(5):273-7
   PubMedGoogle Scholar
• Fabian RH, Hulsebosch CE. Plasma nerve growth factor access to the postnatal central nervous system. Brain Res 1993;611(1):46-52
   PubMedGoogle Scholar
• Tria MA, Fusco M, Vantini G, Mariot R. Pharmacokinetics of nerve growth factor (NGF) following different routes of administration to adult rats. Exp Neurol 1994;127(2):178-83
   PubMed Web of Science ®Google Scholar
• Nguyen CB, Harris L, Szönyi E, et al. Tissue disposition and pharmacokinetics of recombinant human nerve growth factor after acute and chronic subcutaneous administration in monkeys. Drug Metab Dispos 2000;28(5):598-607
   PubMed Web of Science ®Google Scholar
• Petty BG, Cornblath DR, Adornato BT, et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994;36(2):244-6
   PubMed Web of Science ®Google Scholar
• Tan MH, Bryars J, Moore J. Use of nerve growth factor to treat congenital neurotrophic corneal ulceration. Cornea 2006;25(3):352-5
   PubMedGoogle Scholar
• Lambiase A, Coassin M, Sposato V, et al. NGF topical application in patients with corneal ulcer does not generate circulating NGF antibodies. Pharmacol Res 2007;56(1):65-9
   PubMedGoogle Scholar
• Apfel SC, Kessler JA, Adornato BT, et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 1998;51(3):695-702
   PubMed Web of Science ®Google Scholar